China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. Our company was founded in 2002 and listed on NASDAQ in 2009.
China Biologic’s core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based biopharmaceutical products. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Backed by our robust research and development capabilities, we aim to capture substantial value along the entire plasma products value chain, develop technology to enhance our production efficiency, and meet the growing demand of our patients.
As we focus on our core plasma business, we have expanded our product pipeline to include non-plasma biopharmaceutical products and bio-medical device products to complement our market position and expand our base of users in the growing core plasma therapeutic business. With our goal of building a world class biopharmaceutical and biotechnology company, we are committed to improving quality of life and creating value for more patients.
Our principal products are our approved human albumin and IVIG products. Human albumin is principally used to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. IVIG products are primarily used to enhance specific immunity, a defense mechanism by which the human body generates certain immunoglobulin, or antibodies, against invasion by potentially dangerous substances. In a situation where the human body cannot effectively react to these foreign substances, injection of IVIG products can provide sufficient antibodies to neutralize such substances. We also have one chemical drug, placenta polypeptide. In addition, on January 1, 2018, we acquired 80% equity interest in TianXinFu, a medical device company primarily engaging in manufacturing and sale of regenerative medical biomaterial products.
Our approved human albumin, immunoglobulin (including IVIG), factor VIII, PCC and human fibrinogen products all use human plasma as the primary raw material. All of our approved plasma products and the placenta polypeptide products are prescription medicines administered in the form of injections. The artificial dura mater products use extracted collagen as the primary raw material and are applied in neurosurgeries.
See detailed information of our product category here.